Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.53 (
sialidase
)
2,694
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The role of sialic acid linked with
lipoprotein lipase
(
LPL
) in its catalytic activity was studied. When
LPL
was treated with
sialidase
, the molecular weight decreased by 2000. The
sialidase
-treated
LPL
showed unchanged hydrolyzing activity for tributyrin, a water-soluble substrate of esterase, compared with the untreated
LPL
. The
sialidase
-treated
LPL
also showed similar hydrolyzing activity for triolein emulsified with Triton X-100, phosphatidylcholine and phosphatidylethanolamine, whereas it showed significantly increased hydrolyzing activity for triolein emulsified with phosphatidylserine and cardiolipin (152% and 183%, compared with untreated
LPL
, respectively). In addition, the
sialidase
-treated
LPL
showed significantly increased hydrolyzing activity against triolein incorporated into very low-density lipoproteins and chylomicrons (151% and 186%, compared with the untreated
LPL
, respectively). These results suggest that the loss of sialic acids does not modify the function of the catalytic site of
LPL
, but facilitates the interaction of the enzyme with the interface of the surface of substrate lipoproteins.
...
PMID:Modification of lipoprotein lipase catalytic activity by sialic acids. 1035 18